What is Capivasertib? What is the use

Capivasertib (Capivasertib) is a new type of targeted anti-cancer drug that is an oral Akt kinase inhibitor. Akt is a key node in the PI3K/Akt/mTOR signaling pathway. This pathway is frequently activated in a variety of cancers and is closely related to the proliferation, survival, metabolism and drug resistance of tumor cells. Capacetinib blocks this signaling pathway by inhibiting Akt1, Akt2 and Akt3 isoforms, thereby inhibiting tumor growth. This mechanism of action makes it show good potential in the treatment of a variety of solid tumors, especially those with biomarkers such as PIK3CA, AKT1 mutations or PTEN loss.

The main research areas of capositinib include breast cancer, prostate cancer, endometrial cancer and ovarian cancer, etc., especially in estrogen receptor-positive, HER2-negative breast cancer, which has received greater attention. The drug is often used in combination with other therapies, such as Fulvestrant, to treat patients who are resistant to previous endocrine therapy. Multiple overseas clinical trials have shown that in patient groups with clear biomarker screening, capositinib can significantly improve progression-free survival (PFS) and delay disease progression, especially in advanced patients who have failed previous treatments, showing clinically meaningful effects.

In terms of treatment strategy, capositinib is regarded as part of precision medicine, which emphasizes selecting specific patient groups through molecular testing to maximize treatment benefits. With the popularization of molecular diagnostic technology, this drug has broad application prospects in the field of personalized treatment. It is worth noting that the use of capositinib may also be associated with some side effects, such as hyperglycemia, rash, diarrhea, and fatigue. These reactions are related to their mechanisms and require individualized risk assessment and management by professional doctors.

Reference materials:https://www.drugs.com/mtm/capivasertib.html